Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Eli Lilly and Company heads into its October 29 Q3 earnings report with the stock slightly off its recent highs, the analyst consensus firmly bullish, and the central debate narrowing to a single question: how much has Medicare Bridge program pricing hurt Zepbound revenue in the quarter?
The options market reflects mild caution, not outright fear. The put/call ratio has edged up to 1.18, fractionally above its 20-day average of 1.17 and less than half a standard deviation from the mean. That is a long way from the defensive signal territory that would suggest investors are loading up on hedges. The 52-week range runs from 0.76 to 1.37, so the current reading is comfortably mid-range. Short interest contributes little to the tension. Bears hold roughly 0.78% of the free float, down 12% on the week and at a six-month low. The borrow market is entirely unstressed: availability is effectively unlimited, with hundreds of millions of shares in the lending pool, and the cost to borrow is running at 0.36%. None of that points to a market bracing for a squeeze or a sharp move lower. Positioning, on both the options and lending side, looks neutral rather than charged.
The Street remains the most interesting signal ahead of the print. Twenty analysts carry buy-equivalent ratings, with a consensus target of $1,328, implying around 14% upside from Tuesday's close of $1,166.51. The direction of recent analyst action is almost uniformly constructive: Cantor Fitzgerald raised its target to $1,440 on October 8, and RBC Capital reiterated Outperform with a $1,500 target two days later. The only holdout of note is HSBC, which carries a Reduce with a $940 target. Factor scores broadly support the bull view: EPS surprise ranks in the 75th percentile, analyst recommendation divergence is in the 92nd percentile, and EPS momentum over 90 days ranks 79th. The weak spot is valuation. The EV/EBIT factor sits in the 32nd percentile, a reminder that the market is paying a meaningful premium for the growth story, and the PE multiple of roughly 26 times has added slightly over the past month.
The bull and bear cases heading into October 29 are both centred on tirzepatide pricing. Bulls argue the Medicare Bridge program represents only around 10% of US prescriptions and that the volume-for-price trade-off is favourable, with ex-US Mounjaro momentum and a raised guidance range offering a cushion. Bears counter that US Zepbound pricing fell an estimated 18% year on year to around $524 per prescription in Q3, that Verzenio prescriptions declined 2% year on year, and that Trulicity has now fallen more than 20% year on year for three consecutive quarters. If obesity volume growth slows faster than those pricing declines, operating margins come under pressure.
The most relevant alt-data colour comes from CMS Medicaid drug utilisation data, which showed Medicaid dollars reimbursed for Lilly up 14% year on year in Q1 2026. This is not a leading indicator for the print and the dataset has not been measured to lead Lilly's reported figures, but it does confirm the government-payer channel was expanding earlier in the year. Whether that trajectory held through Q3 alongside the Bridge program headwind is part of what October 29 resolves.
Lilly has beaten estimates at each of its last two prints and posted a 6.8% one-day move after August's Q2 results, followed by a further 9.4% gain over the next five days. The Q1 print produced a more modest 2.7% day-one move. Against that backdrop, and with the stock trading roughly 1% below where it was two days ago, the setup heading into the report is one where the positioning is clean but the pricing debate is live.
What to watch is simple: the Q3 Zepbound net revenue figure and any revision to the $85 billion to $87 billion full-year sales guidance, because those two numbers will settle the Bridge program argument one way or the other.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
